

SPECIAL STATUS APPLICATION

Appl. No. 10/659,413

Reply to Final Office Action mailed April 12, 2005

Amendment and Reply AF dated May 19, 2005

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-31 (canceled)

32. (currently amended) An antiseptic composition comprising at least one salt of ethylene diamine tetraacetic acid (EDTA) and a solvent, wherein the at least one EDTA salt comprises tetra-sodium EDTA and is at a concentration of at least 2.0% (w/v) and less than 15% (w/v), wherein the antiseptic composition has a bactericidal effect over a broad spectrum of microbes, wherein the antiseptic composition has a pH of at least 9.5, and wherein the antiseptic composition is packaged in a sterile, pyrogen-free form ~~safe and biocompatible, at least in modest volumes, in a patient's bloodstream.~~

Claim 33. (canceled)

34. (currently amended) A composition of any of claims 32, ~~54, 55,~~ or 56, comprising tri-sodium and tetra-sodium EDTA.

Claims 35-36 (canceled)

37. (currently amended) A composition of any of claims ~~32, 54, 55,~~ or 56, wherein the solvent comprises less than 10% (v/v) ethanol and water.

Claim 38. (canceled)

39. (currently amended) A composition of any of claims ~~32, 54, 55~~ or 56, wherein the solvent comprises saline.

13317.1001CIP

2/11

BEST AVAILABLE COPY

SPECIAL STATUS APPLICATION

Appl. No. 10/659,413

Reply to Final Office Action mailed April 12, 2005

Amendment and Reply AF dated May 19, 2005

40. (currently amended) A composition of any of claims 32, 54, 55 or 56, that is substantially free from an ~~agent~~ active substance other than EDTA salt(s) having antimicrobial and/or antifungal activity that is at least 50% of the anti-microbial and/or antifungal activity of a sodium EDTA salt composition in aqueous solution at a concentration of 4% (w/v) and at a pH of 10.5.
41. (previously presented) A composition of claim 32 formulated for topical application to surfaces and objects.
42. (currently amended) A composition of any of claims 32, 54, 55, or 56, comprising tri- and tetra-sodium EDTA salts in an aqueous solvent at a concentration of between 2.0% and 8.0% (w/v) EDTA salt(s).
- Claim 43. (canceled)
44. (currently amended) A composition of ~~any of claims 32, 54, or 55, or 56,~~ in a sterile, pyrogen-free form.
45. (currently amended) A composition provided in a dry or partially hydrated formulation that, upon reconstitution with a solvent, forms an antiseptic composition of any of claims 32, 54, 55, or 56.
46. (currently amended) A composition of any of claims 32, 54, 55, or 56 in sterile condition in a pre-filled syringe.
47. (currently amended) A composition of any of claims: 32, 54, 55, or 56 ~~in a sterile condition~~ in a single-dosage vial.

Claims 48-54 (canceled)

13317.1001CIP

3/11

BEST AVAILABLE COPY

SPECIAL STATUS APPLICATION

Appl. No. 10/659,413

Reply to Final Office Action mailed April 12, 2005

Amendment and Reply AF dated May 19, 2005

55. (currently amended) An antiseptic composition comprising at least one salt of ethylene diamine tetraacetic acid (EDTA) and a solvent, wherein the at least one EDTA salt comprises tetra-sodium EDTA and is at a concentration of at least 2.0% (w/v) and less than 15% (w/v), wherein the antiseptic composition has a bactericidal effect over a broad spectrum of microbes, wherein the antiseptic composition has a pH of at least 9.5, wherein the solvent comprises saline, and wherein the antiseptic composition has an osmolarity of from 240 – 500 mOsM/Kg.
56. (currently amended) A lock flush composition comprising at least one salt of ethylene diamine tetraacetic acid (EDTA) and a solvent, wherein the at least one EDTA salt comprises tetra-sodium EDTA and is at a concentration of at least 2.0% (w/v) and less than 15% (w/v), wherein the lock flush composition has a pH of at least 9.5, wherein the lock flush composition is sterile and pyrogen-free, and wherein the lock flush composition is ~~safe~~ and biocompatible for use in in-dwelling access catheters, urinary catheters, nasal tubes and throat tubes .

BEST AVAILABLE COPY